Acucela 4429-202 SEATTLE

Research Title: A Phase 2b/3 Multicenter, Randomized, Double-Masked, Dose-Ranging Study Comparing the Efficacy and Safety of Emixustat Hydrochloride (ACU-4429) With Placebo for the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration.

Sponsor: Acucela Inc

Principal Investigator: Mark J. Rivellese, M.D.

Description: The purpose of this study is to determine if emixustat hydrochloride (ACU-4429) reduces the rate of progression of geographic atrophy compated to placebo in subjects with dry age-related macular degeneration.

Start Date: March 2013

Recruitment: Completed

Project Personnel: Leslie Marcus, CCRC

Location(s): Tucker; 1462 Montreal Road West, Suite 412, Tucker, GA 30084